In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia

Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: Optimization studies and demonstration of in vivo efficacy

(2013) Mark S. Plummer et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Select 3′,5′-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain

(2013) Michy P. Kelly et al.   CELLULAR SIGNALLING

Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801

(2012) Olga A.H. Reneerkens et al.   BEHAVIOURAL BRAIN RESEARCH

Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia

(2012) Neil S. Cutshall et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Functional roles of neurotransmitters and neuromodulators in the dorsal striatum

(2012) J. Do et al.   LEARNING & MEMORY

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

(2012) Sean M. Smith et al.   NEUROPHARMACOLOGY

The distribution of phosphodiesterase 2A in the rat brain

(2012) D.T. Stephenson et al.   NEUROSCIENCE

Hippocampal nitric oxide contributes to sex difference in affective behaviors

(2012) Y. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia

(2011) Christopher J. Helal et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats

(2011) Joshua S. Rodefer et al.   NEUROPHARMACOLOGY

Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats

(2011) John P. Redrobe et al.   PSYCHOPHARMACOLOGY

Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents

(2010) Christopher Schmidt   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia

(2010) Samantha L. McLean et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: A meta-analysis

(2010) Anne-Kathrin J. Fett et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism

(2010) Joanna C. Neill et al.   PHARMACOLOGY & THERAPEUTICS

Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model

(2010) Pascal Jean Denis Goetghebeur et al.   PSYCHOPHARMACOLOGY

Mutant Mouse Models: Phenotypic Relationships to Domains of Psychopathology and Pathobiology in Schizophrenia

(2010) C. M. P. O'Tuathaigh et al.   SCHIZOPHRENIA BULLETIN

Translational Aspects of the Novel Object Recognition Task in Rats Abstinent Following Sub-Chronic Treatment with Phencyclidine (PCP): Effects of Modafinil and Relevance to Cognitive Deficits in Schizophrenia

(2010) John P. Redrobe et al.   Frontiers in Psychiatry

Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats

(2009) Trine Damgaard et al.   BEHAVIOURAL BRAIN RESEARCH

Discrimination Learning, Reversal, and Set-Shifting in First-Episode Schizophrenia: Stability Over Six Years and Specific Associations with Medication Type and Disorganization Syndrome

(2009) Verity C. Leeson et al.   BIOLOGICAL PSYCHIATRY

Conditioned Avoidance Response in the Development of New Antipsychotics

(2009) M-L. Wadenberg   CURRENT PHARMACEUTICAL DESIGN

Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species

(2009) Diane T. Stephenson et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to d-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons

(2009) Florence Sotty et al.   JOURNAL OF NEUROCHEMISTRY

Chronic infusion of PCP via osmotic mini-pumps: A new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance

(2009) Christian Spang Pedersen et al.   JOURNAL OF NEUROSCIENCE METHODS

Anxiolytic Effects of Phosphodiesterase-2 Inhibitors Associated with Increased cGMP Signaling

(2009) A. Masood et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Attenuation of Phencyclidine-Induced Object Recognition Deficits by the Combination of Atypical Antipsychotic Drugs and Pimavanserin (ACP 103), a 5-Hydroxytryptamine2A Receptor Inverse Agonist

(2009) S. Snigdha et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia

(2009) Jared W. Young et al.   PHARMACOLOGY & THERAPEUTICS

Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set-shifting

(2009) Brian Villumsen Broberg et al.   PSYCHOPHARMACOLOGY

Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice

(2009) Philipp Singer et al.   PSYCHOPHARMACOLOGY

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms

(2009) Nagi Idris et al.   PSYCHOPHARMACOLOGY

A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats

(2008) Samantha L. McLean et al.   BEHAVIOURAL BRAIN RESEARCH

Evaluation of a neurodevelopmental model of schizophrenia—Early postnatal PCP treatment in attentional set-shifting

(2008) Brian Villumsen Broberg et al.   BEHAVIOURAL BRAIN RESEARCH

Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion

(2008) Eva L. van Donkelaar et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Antipsychotic-Like Effect of Retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic Acid Ester], a KCNQ Potassium Channel Opener, via Modulation of Mesolimbic Dopaminergic Neurotransmission

(2008) F. Sotty et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational study

(2008) Pascal Goetghebeur et al.   PSYCHOPHARMACOLOGY

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

(2008) Olga A. H. Reneerkens et al.   PSYCHOPHARMACOLOGY

Reinforcement and Reversal Learning in First-Episode Psychosis

(2008) G. K. Murray et al.   SCHIZOPHRENIA BULLETIN